Klinik und Poliklinik für Geburtshilfe und Frauengesundheit
Klinikum / Johannes Gutenberg-Universität Mainz
Almstedt, K; Hasenburg, A
Wechseljahresbeschwerden – Hormonmangel nach der gynäko-onkologischen TherapieFrauenheilkunde up2date. Bd. 13. H. 5. 2019 S. 475-485
Schmalfeldt, Barbara; Brambs, Christine; Burges, Alexander et al.
What is the evidence for lymphadenectomy in presumed early ovarian cancer?ARCHIVES OF GYNECOLOGY AND OBSTETRICS. Bd. 299. H. 1. 2019 S. 1-5
Wiesmann, Nadine; Kluenker, Martin; Demut, Philipp et al.
Zinc overload mediated by zinc oxide nanoparticles as innovative anti-tumor agentJOURNAL OF TRACE ELEMENTS IN MEDICINE AND BIOLOGY. Bd. 51. 2019 S. 226-234
Verhoeven, Carole; Schmidt, Marcus; Hoenig, Arnd et al.
(E)stetrol for treatment of advanced ER+ breast cancerCANCER RESEARCH. Bd. 78. H. 4. 2018
Surowy, Harald; Varga, Dominic; Burwinkel, Barbara et al.
A low-frequency haplotype spanning SLX4/FANCP constitutes a new risk locus for early-onset breast cancer (< 60 years) and is associated with reduced DNA repair capacityINTERNATIONAL JOURNAL OF CANCER. Bd. 142. H. 4. 2018 S. 757-768
Kebenko, Maxim; Goebeler, Marie-Elisabeth; Wolf, Martin et al.
A multicenter phase 1 study of solitomab (MT110, AMG 110), a bispecific EpCAM/CD3 T-cell engager (BiTE (R)) antibody construct, in patients with refractory solid tumorsONCOIMMUNOLOGY. Bd. 7. H. 8. 2018
Schmidt, Marcus; Decker, Thomas; Fehm, Tanja et al.
A phase II study of metronomic daily oral vinorelbine as first-line chemotherapy in advanced/metastatic hormone receptor positive (HR plus ) / human epidermal growth factor receptor 2 negative (HER2-) breast cancer resistant to endocrine therapy - VinoMetroCANCER RESEARCH. Bd. 78. H. 4. 2018
Coombes, R. C.; Tovey, Holly; Kilburn, Lucy et al.
A phase III multicentre double blind randomised trial of celecoxib versus placebo in primary breast cancer patients (REACT - Randomised EuropeAn celecoxib trial)CANCER RESEARCH. Bd. 78. H. 4. 2018
Mueller, V.; Park-Simon, T. -W.; Huober, J. et al.
A randomized, double-blinded pivotal study of tucatinib (ONT-380) vs. placebo in combination with capecitabine and trastuzumab in patients with pretreated HER2-pos. unresectable locally advanced or metastatic breast cancer: HER2CLIMBONCOLOGY RESEARCH AND TREATMENT. Bd. 41. 2018 S. 28-28
Loibl, Sibylle; Barinoff, Jana; Seiler, Sabine et al.
A randomized, open-label, multi-center phase IV study evaluating palbociclib plus endocrine treatment versus a chemotherapy-based treatment strategy in patients with hormone receptor-positive, HER2-negative metastatic breast cancer in a real world setting (PADMA)CANCER RESEARCH. Bd. 78. H. 4. 2018